According to Gulf Pharmaceutical Industries (Julphar), the financial position in 2024 remains stable with manageable revenues. Vice-President of the company, Adnan Yahia, noted: "We continue to focus on strengthening our business, improving operational efficiency, and developing our operations. Despite a challenging year due to the pandemic, we have made notable progress in our strategic initiatives." He also added that Julphar is successfully handling external environment challenges and that the company continues to expand its product line and improve its manufacturing processes. Julphar, one of the leading pharmaceutical companies in the Gulf region, remains on a path of growth and innovation, despite the complexities caused by the pandemic.
